Moors & Cabot’s State Street SPDR S&P Biotech ETF XBI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $341K | Sell |
2,669
-78
| -3% | -$9.74K | 0.01% | 659 |
|
|
2025
Q4 | $335K | Buy |
2,747
+30
| +1% | +$3.44K | 0.01% | 649 |
|
|
2025
Q3 | $272K | Buy |
2,717
+100
| +4% | +$9.01K | 0.01% | 709 |
|
|
2025
Q2 | $217K | Sell |
2,617
-1,365
| -34% | -$109K | 0.01% | 773 |
|
|
2025
Q1 | $323K | Sell |
3,982
-340
| -8% | -$30.4K | 0.02% | 615 |
|
|
2024
Q4 | $389K | Sell |
4,322
-315
| -7% | -$30.5K | 0.02% | 578 |
|
|
2024
Q3 | $458K | Sell |
4,637
-2,300
| -33% | -$226K | 0.02% | 517 |
|
|
2024
Q2 | $643K | Buy |
6,937
+162
| +2% | +$14.5K | 0.03% | 406 |
|
|
2024
Q1 | $643K | Buy |
6,775
+3,305
| +95% | +$307K | 0.03% | 418 |
|
|
2023
Q4 | $310K | Sell |
3,470
-75
| -2% | -$5.57K | 0.02% | 618 |
|
|
2023
Q3 | $259K | Sell |
3,545
-199
| -5% | -$15.9K | 0.02% | 643 |
|
|
2023
Q2 | $312K | Sell |
3,744
-475
| -11% | -$39.7K | 0.02% | 601 |
|
|
2023
Q1 | $322K | Sell |
4,219
-50
| -1% | -$4.15K | 0.02% | 578 |
|
|
2022
Q4 | $354K | Buy |
4,269
+237
| +6% | +$19.2K | 0.02% | 522 |
|
|
2022
Q3 | $320K | Buy |
4,032
+87
| +2% | +$7.33K | 0.02% | 538 |
|
|
2022
Q2 | $293K | Sell |
3,945
-200
| -5% | -$15K | 0.02% | 571 |
|
|
2022
Q1 | $373K | Sell |
4,145
-825
| -17% | -$76.2K | 0.02% | 562 |
|
|
2021
Q4 | $556K | Sell |
4,970
-25
| -0.5% | -$3.02K | 0.03% | 431 |
|
|
2021
Q3 | $629K | Buy |
4,995
+152
| +3% | +$19.6K | 0.04% | 382 |
|
|
2021
Q2 | $656K | Buy |
4,843
+192
| +4% | +$25.2K | 0.05% | 352 |
|
|
2021
Q1 | $632K | Buy |
4,651
+183
| +4% | +$27.4K | 0.05% | 342 |
|
|
2020
Q4 | $630K | Buy |
4,468
+215
| +5% | +$27.5K | 0.05% | 310 |
|
|
2020
Q3 | $474K | Buy |
4,253
+470
| +12% | +$52.7K | 0.04% | 341 |
|
|
2020
Q2 | $421K | Buy |
3,783
+831
| +28% | +$81.8K | 0.04% | 352 |
|
|
2020
Q1 | $229K | Buy |
2,952
+81
| +3% | +$7.17K | 0.03% | 462 |
|
|
2019
Q4 | $275K | Buy |
+2,871
| New | +$248K | 0.03% | 483 |
|
|
2018
Q2 | – | Sell |
-4,991
| Closed | -$438K | – | 607 |
|
|
2018
Q1 | $438K | Buy |
4,991
+342
| +7% | +$31.2K | 0.06% | 357 |
|
|
2017
Q4 | $396K | Sell |
4,649
-59
| -1% | -$4.94K | 0.05% | 365 |
|
|
2017
Q3 | $407K | Buy |
4,708
+1,582
| +51% | +$127K | 0.06% | 345 |
|
|
2017
Q2 | $241K | Buy |
+3,126
| New | +$222K | 0.04% | 426 |
|
|
2017
Q1 | – | Sell |
-3,378
| Closed | -$200K | – | 567 |
|
|
2016
Q4 | $200K | Buy |
+3,378
| New | +$209K | 0.03% | 482 |
|
|
2016
Q1 | – | Sell |
-2,864
| Closed | -$200K | – | 557 |
|
|
2015
Q4 | $200K | Buy |
+2,864
| New | +$195K | 0.04% | 448 |
|
|
2015
Q2 | – | Sell |
-8,715
| Closed | -$655K | – | 547 |
|
|
2015
Q1 | $655K | Buy |
8,715
+3
| +0% | +$210 | 0.11% | 223 |
|
|
2014
Q4 | $543K | Sell |
8,712
-798
| -8% | -$45.5K | 0.09% | 248 |
|
|
2014
Q3 | $496K | Sell |
9,510
-435
| -4% | -$22.2K | 0.08% | 255 |
|
|
2014
Q2 | $509K | Buy |
+9,945
| New | +$448K | 0.09% | 258 |
|
Other funds holding XBI
Moors & Cabot's XBI Position: Q1 2026 in Review
Moors & Cabot reduced its State Street SPDR S&P Biotech ETF (XBI) stake by 2.8% in Q1 2026, selling an estimated $9.74K and leaving 2,669 shares worth $341K. The position accounts for 0.01% of the portfolio, ranked #659.
Moors & Cabot first reported a position in XBI in Q2 2014 and has held it in 36 quarters since. The position peaked at $656K in Q2 2021. 815 funds tracked by Wall St. Rank hold XBI as of Q1 2026.
- Moors & Cabot held 2,669 shares of State Street SPDR S&P Biotech ETF worth $341K as of Q1 2026.
- Moors & Cabot sold 78 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $9.74K.
- State Street SPDR S&P Biotech ETF made up 0.01% of Moors & Cabot's portfolio in Q1 2026, its #659 holding.
- Moors & Cabot first reported a position in State Street SPDR S&P Biotech ETF in Q2 2014 and has held it in 36 quarters since.
- Moors & Cabot's State Street SPDR S&P Biotech ETF position peaked at $656K in Q2 2021.
- 815 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.
Based on Moors & Cabot's 13F filing for Q1 2026, filed 8 May 2026.